Ionizing radiation attracts tumor targeting and apoptosis by radiotropic lysyl oxidase traceable nanoparticles

Publication date: Available online 10 December 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Wheemoon Cho, Min Sup Kim, Kee-Ho Lee, Sang Jun Park, Hyun-Jin Shin, Yong Jin Lee, Sang Bum Kim, Youngsook Son, Chun-Ho KimAbstractLysyl oxidase (LOX) is a cell-secreted amine oxidase that crosslinks collagen and elastin in extracellular microenvironment. LOX-traceable nanoparticles (LOXab-NPs) consisting of LOX antibodies (LOXab) and paclitaxel, can accumulate at high concentrations at radiation-treated target sites, as a tumor-targeting drug carrier for chemotherapy. Tumor-targeting and anticancer effect of PLGA based LOXab-NPs in vitro and in vivo were evaluated at radiation-targeted site. In the in vivo A549 lung carcinoma xenograft model, we showed highly specific tumor targeting (above 7.0 times higher) of LOXab-NPs on irradiated tumors. Notably, systemically administered NPs delayed tumor growth, reducing tumor volumes by more than 2 times compared with non-irradiated groups (222% vs.>500%) over 2 weeks. Radiotropic LOXab-NPs, which can be served as chemotherapeutic vehicles for combined targeted chemo-radiotherapy in clinical oncology.Graphical AbstractLOX-traceable PLGA based nanoparticles consisting of LOX antibodies and paclitaxel (LOX-NPs(P)), which can accumulate at high concentrations at radiation-treated target sites, as a tumor-targeting drug carrier for chemotherapy. Biodistribution of NPs on extracted organs from sacrificed mice after ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research